Diagenode

The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.


Wade MA, Jones D, Wilson L, Stockley J, Coffey K, Robson CN, Gaughan L

Endocrine therapy has successfully been used to treat estrogen receptor (ER)-positive breast cancer, but this invariably fails with cancers becoming refractory to treatment. Emerging evidence has suggested that fluctuations in ER co-regulatory protein expression may facilitate resistance to therapy and be involved in breast cancer progression. To date, a small number of enzymes that control methylation status of histones have been identified as co-regulators of ER signalling. We have identified the histone H3 lysine 9 mono- and di-methyl demethylase enzyme KDM3A as a positive regulator of ER activity. Here, we demonstrate that depletion of KDM3A by RNAi abrogates the recruitment of the ER to cis-regulatory elements within target gene promoters, thereby inhibiting estrogen-induced gene expression changes. Global gene expression analysis of KDM3A-depleted cells identified gene clusters associated with cell growth. Consistent with this, we show that knockdown of KDM3A reduces ER-positive cell proliferation and demonstrate that KDM3A is required for growth in a model of endocrine therapy-resistant disease. Crucially, we show that KDM3A catalytic activity is required for both ER-target gene expression and cell growth, demonstrating that developing compounds which target demethylase enzymatic activity may be efficacious in treating both ER-positive and endocrine therapy-resistant disease.

Tags
IP-Star
Antibody
IP-Star Compact

Share this article

Published
January, 2015

Source

Products used in this publication

  • ChIP-seq Grade
    C15410056
    H3K9me3 Antibody
  • Antibody ChIP icon
    C15410065
    H3K9me1 Antibody - ChIP Grade
  • Antibody ChIP icon
    C15410060
    H3K9me2 Antibody
  • Mouse IgG
    C15410206
    Rabbit IgG
  • Compact Automated System
    B03000002
    IP-Star® Compact Automated System

Events

  • Virtual ChIL-seq webinar
    Diagenode
    Dec 8, 2021
 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics